Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
-
Published:2017-02
Issue:1
Volume:15
Page:23-30.e2
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Necchi Andrea,
Pond Gregory R.,
Raggi Daniele,
Giannatempo Patrizia,
Vogelzang Nicholas J.,
Grivas PetrosORCID,
Galsky Matthew D.,
Bellmunt Joaquim,
Sonpavde Guru
Reference46 articles.
1. First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients;Abida;Hematol Oncol Clin North Am,2015
2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000
3. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study 30987;Bellmunt;J Clin Oncol,2012
4. The impact of adding taxanes to gemcitabine and platinum chemotherapy for the first-line therapy of advanced or metastatic urothelial cancer: a systematic review and meta-analysis;Giannatempo;Eur Urol,2016
5. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community;Sonpavde;Clin Genitourin Cancer,2012
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献